Relmada Therapeutics, Inc.
RLMD
$6.27
$0.559.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.23% | 94.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.64% | 68.81% | |||
| Operating Income | -11.64% | -68.81% | |||
| Income Before Tax | 4.11% | -96.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.11% | -96.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.11% | -96.88% | |||
| EBIT | -11.64% | -68.81% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 32.35% | -6.97% | |||
| Normalized Basic EPS | 23.45% | 8.11% | |||
| EPS Diluted | 32.35% | -6.97% | |||
| Normalized Diluted EPS | 23.45% | 8.11% | |||
| Average Basic Shares Outstanding | 41.74% | 84.07% | |||
| Average Diluted Shares Outstanding | 41.74% | 84.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||